Despite Enrollment In Medicare Prescription Drug Coverage, Over Half of All Seniors Pay Full Cost for Many Generic Drugs
When seniors with Medicare drug coverage are paying the full cost for their generic seizure or asthma medications, it’s concerning. When the share of patients who have paid the full cost for certain generic drugs increases by nearly 20 percentage points over three years, it’s alarming. And when the price that patients with insurance are […]
HHS OIG Report Demonstrates Need for Changes to Part D to Increase Biosimilar Use
Biosimilars provide more options for care at a lower cost for patients, but due to Medicare’s perverse incentives, many PBMs and health plans have been slow to prioritize biosimilars, leavings savings on the table. Last week, the HHS Inspector General (OIG) released an important analysis that drives home just how poorly Medicare plans are doing […]
AAM Statement on Avalere Medicare Part D Analysis
AAM Critical of Medicare Part D Plans for Placing Generics on Higher Tiers WASHINGTON, D.C. (March 11, 2021) — Today’s data highlights the continued worsening of generic drug coverage in Medicare Part D. Even as generic drugs continue to decline in price, seniors are forced to pay more because of formulary design. It is vital […]
Avalere Analysis Finds Medicare Part D Patients Are Paying More For Their Lower-Cost Generics
WASHINGTON, DC (February 13, 2020) — Avalere’s latest findings add to the growing body of evidence that Medicare Part D Plans are discouraging the use of lower-cost generic drugs. For the first time there are more generics on non-generic tiers. This forces America’s patients to pay more for their generic drugs and causes higher taxpayer spending […]
